glp-1 business GLP 1 Template for Weight Loss Clinic Medspa Banner Sign Glp1 Promotion Sign Weightloss Marketing Semagluetide Weight Loss The GLP-1 effect on MedTech

1,000 mL Lactated Ringer's unless otherwise specified

Discontinuing treatment can result in weight regain, so a comprehensive, long-term approach is crucial

Food and Drug Administration first approved semaglutide as Ozempic for type 2 diabetes in 2017 and as Wegovy for chronic weight management in 2021, and approved tirzepatide as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023

There have been post-marketing reports of acute pancreatitis associated with incretin mimetics

GLP-1 medications can be safe and effective when prescribed appropriately and monitored by a healthcare professional

15-22% body-weight loss over 6-12 months